Vitiligo
☆ Tamin'ny valin'ny Stiftung Warentest 2022 avy any Alemaina, ny fahafaham-pon'ny mpanjifa amin'ny ModelDerm dia ambany kely noho ny fifampidinihana telemedicine karama.
Vitiligo amin'ny rantsantanana dia sarotra kokoa ny fitsaboana noho ny faritra hafa. Ankoatra ny maha ratsy tarehy, ny vitiligo dia ara-dalàna ary tsy mifindra. Ao amin'ny dermatology, ny fitsaboana mahomby indrindra dia ny phototherapy na ny fitsaboana laser (excimer) in-2-3 isan-kerinandro mandritra ny 1 taona farafahakeliny. Raha tsy afaka mandeha any amin'ny hopitaly matetika ianao noho ny antony ara-bola na noho ianao sahirana, dia azonao atao ny manandrana milina phototherapy izay ankatoavina ho an'ny fampiasana an-trano.
vitiligo hodimaso
Vitiligo eo amin'ny tanana
References
Vitiligo dia aretin'ny hoditra mahazatra izay miteraka tasy amin'ny hoditra fotsy noho ny fahaverezan'ny melanocytes. Ny fikarohana vao haingana dia mampiseho fa aretina autoimmune io. Na dia hita matetika ho toy ny olan'ny kosmetika aza izy io, dia mety hisy fiantraikany lalina eo amin'ny fahasalamana ara-tsaina sy ny fiainana andavanandro. Tamin'ny taona 2011, nanasokajy karazana antsoina hoe segmental vitiligo mitokana amin'ny hafa ny manam-pahaizana.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Ny marary vitiligo mavitrika dia manana safidy fitsaboana maromaro, toy ny glucocorticoids systemic, phototherapy, ary immunosuppressants systemic. Ny mararin'ny vitiligo stable dia mety hahita fanamaivanana amin'ny corticosteroids topical, inhibitors calcineurin topical, phototherapy, ary ny fomba famindrana. Ny fandrosoana vao haingana amin'ny fahatakarana ny fizotran'ny vitiligo dia nitarika ny fivoaran'ny fitsaboana mikendry. Amin'izao fotoana izao, ny JAK inhibitors no tena mampanantena indrindra, manome ny fandeferana tsara sy ny vokatra azo ampiasaina, na dia eo aza ny mety hisian'ny otrikaretina miafina sy ny voka-dratsin'ny rafitra mahazatra amin'ny fanafody immunosuppressive hafa. Ny fikarohana mitohy dia mikendry ny hamantatra ireo cytokines fototra tafiditra amin'ny fivoaran'ny vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Ny fanakanana ireo cytokine ireo dia nampiseho fampanantenana tamin'ny modely biby sy ny marary sasany. Fanampin'izany, mandeha ny fanadihadiana momba ny miRNA-based therapeutics sy adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Tsy misy fanafody fantatra amin'ny vitiligo. Ho an'ireo manana hoditra maivana, ecran sunscreen sy maquillage ihany no aroso matetika. Ny safidy fitsaboana hafa dia mety ahitana crème steroid na phototherapy.
○ Fitsaboana
#Phototherapy
#Excimer laser
#Tacrolimus ointment